127 related articles for article (PubMed ID: 7843643)
1. Safety of plasma derivatives.
Ingerslev J
Haemostasis; 1994; 24(5):311-23. PubMed ID: 7843643
[TBL] [Abstract][Full Text] [Related]
2. Strategies for viral inactivation.
Horowitz B; Ben-Hur E
Curr Opin Hematol; 1995 Nov; 2(6):484-92. PubMed ID: 9372040
[TBL] [Abstract][Full Text] [Related]
3. Safety procedures of coagulation factors.
Jorquera JI
Haemophilia; 2007 Dec; 13 Suppl 5(Suppl 5):41-6. PubMed ID: 18078396
[TBL] [Abstract][Full Text] [Related]
4. Transfusion-transmitted infection in hemophilia in developing countries.
Yee TT; Lee CA
Semin Thromb Hemost; 2005 Nov; 31(5):527-37. PubMed ID: 16276461
[TBL] [Abstract][Full Text] [Related]
5. [Safety of transfusion therapy with special emphasis on inactivated viruses in products made from human blood].
Patko MS; Balija M; Grgicević D
Lijec Vjesn; 1995; 117(9-10):216-21. PubMed ID: 8643012
[TBL] [Abstract][Full Text] [Related]
6. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
7. Virus safety of prothrombin complex concentrates and factor IX concentrates.
Seitz R; Dodt J
Thromb Res; 1999 Aug; 95(4 Suppl 1):S19-23. PubMed ID: 10499905
[TBL] [Abstract][Full Text] [Related]
8. Viral safety of clotting factor concentrates.
Fricke WA; Lamb MA
Semin Thromb Hemost; 1993; 19(1):54-61. PubMed ID: 8456324
[TBL] [Abstract][Full Text] [Related]
9. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates.
Burnouf T
Biologicals; 1992 Jun; 20(2):91-100. PubMed ID: 1389114
[TBL] [Abstract][Full Text] [Related]
10. [Clinical use of virally inactived plasma. The experience of Blood Transfusion Unit in Mantova, Italy].
Lepri D; Capuzzo E; Mattioli AV; Dall'Oglio D; Sgarioto V; Terenziani I; Caramaschi G; Manzato F; Franchini M
Recenti Prog Med; 2013 Mar; 104(3):106-11. PubMed ID: 23548954
[TBL] [Abstract][Full Text] [Related]
11. Risks and side effects of therapy with plasma and plasma fractions.
MacLennan S; Barbara JA
Best Pract Res Clin Haematol; 2006; 19(1):169-89. PubMed ID: 16377549
[TBL] [Abstract][Full Text] [Related]
12. Viral safety of human plasma-derived medicinal products: impact of regulation requirements.
Velthove KJ; Over J; Abbink K; Janssen MP
Transfus Med Rev; 2013 Jul; 27(3):179-83. PubMed ID: 23886505
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage.
Scott E; Puca K; Heraly J; Gottschall J; Friedman K
Transfusion; 2009 Aug; 49(8):1584-91. PubMed ID: 19413730
[TBL] [Abstract][Full Text] [Related]
14. [Safety of plasma products may be improved].
Wahlberg T
Lakartidningen; 1995 Dec; 92(51-52):4869-70. PubMed ID: 8544500
[No Abstract] [Full Text] [Related]
15. Blood derived products in pediatrics: New laboratory tools for optimizing potency assignment and reducing side effects.
Amiral J; Seghatchian J
Transfus Apher Sci; 2017 Apr; 56(2):107-117. PubMed ID: 28343935
[TBL] [Abstract][Full Text] [Related]
16. [Safety of plasma-derived factor concentrates: an example of pharmacovigilance with fibrinogen and factor XIII-concentrate].
Spannagl M; Joch Ch; Heindl B
Hamostaseologie; 2006 Aug; 26(3 Suppl 1):S36-40. PubMed ID: 16953291
[TBL] [Abstract][Full Text] [Related]
17. The Evolution of the Safety of Plasma Products from Pathogen Transmission-A Continuing Narrative.
Farrugia A
Pathogens; 2023 Feb; 12(2):. PubMed ID: 36839590
[TBL] [Abstract][Full Text] [Related]
18. Specific inactivation of viruses which can potentially contaminate blood products.
Horowitz B
Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
[TBL] [Abstract][Full Text] [Related]
19. Perioperative factor concentrate therapy.
Tanaka KA; Esper S; Bolliger D
Br J Anaesth; 2013 Dec; 111 Suppl 1():i35-49. PubMed ID: 24335398
[TBL] [Abstract][Full Text] [Related]
20. Plasma and plasma derivatives in therapeutic plasmapheresis.
McLeod BC
Transfusion; 2012 May; 52 Suppl 1():38S-44S. PubMed ID: 22578370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
